Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives $12.83 Average Price Target from Analysts

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has been assigned a consensus recommendation of “Buy” from the five analysts that are presently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $12.38.

Several equities research analysts have commented on CRVS shares. StockNews.com cut shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. HC Wainwright started coverage on shares of Corvus Pharmaceuticals in a research report on Thursday, January 2nd. They set a “buy” rating and a $11.00 price target on the stock. Mizuho raised shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. LADENBURG THALM/SH SH boosted their price target on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Finally, Oppenheimer boosted their price objective on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ:CRVS opened at $6.03 on Thursday. The company’s 50-day moving average price is $7.62 and its two-hundred day moving average price is $5.36. Corvus Pharmaceuticals has a one year low of $1.30 and a one year high of $10.00. The stock has a market capitalization of $387.47 million, a PE ratio of -6.48 and a beta of 1.07.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Nwam LLC acquired a new position in Corvus Pharmaceuticals in the 3rd quarter valued at about $53,000. XTX Topco Ltd acquired a new position in Corvus Pharmaceuticals in the 3rd quarter valued at about $74,000. Virtu Financial LLC bought a new position in Corvus Pharmaceuticals in the 3rd quarter valued at approximately $83,000. Oppenheimer & Co. Inc. bought a new position in Corvus Pharmaceuticals in the 3rd quarter valued at approximately $89,000. Finally, Cubist Systematic Strategies LLC bought a new position in Corvus Pharmaceuticals in the 2nd quarter valued at approximately $44,000. 46.64% of the stock is currently owned by institutional investors and hedge funds.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.